Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by A. Tamta
Total Records ( 3 ) for A. Tamta
  A. Tamta , M. Chaudhary and R. Sehgal
  The objective of current study was to evaluate deleterious effects of a potential combination of cefpirome, a member of the latest class of broad-spectrum cephalosporins, in combination of β-lactamase inhibitor, sulbactum. To assess the toxicity profile of fixed dose regimen Pirotum (Cefpirome+Sulbactum in 2:1 ratio), a repeated dose subacute toxicity study was conducted on Swiss albino mice and Wistar rat (male and female). Three different dose levels (30, 60 and 120 mg kg-1) of combination were administered for twenty eight days. Physical parameters, hematological parameters and biochemical parameters related to liver toxicity and nephrotoxicity were evaluated as end point parameters. Findings of present study were also supported by hematological as well as histopathology parameters. Data of current study indicated that Pirotum exerted no deleterious effect on blood, liver and kidney function as no alteration was observed in biochemical parameters at any dose level.
  A. Tamta and M. Chaudhary
  The present study investigated safety/toxicity profile of Sulbactomax (Ceftriaxone-Sulbactam for injection), a fixed dose combination, in Mus musculus mice and SD rats at three dose levels, 10, 50 and 150 mg kg-1 ranging from asymptomatic to high dose. Sulbactomax was introduced in order to enhance the antimicrobial efficacy and to combat resistance towards beta-lactamase producing bacteria. The combination has been reported to be highly effective as well as synergistic for many resistant strains and carry the potential for its usage in empirical therapy for various bacterial infections. To establish the safety profile of combination, 28 days repeated dose sub-acute toxicity study was conducted on mice and rat (male and female). Various hematological parameters were studied in addition to physiological and biochemical parameters in order to study toxicity profile of Sulbactomax. There were no signs of toxicity observed at any of the dose levels used in this study. Animals from control and different treated groups exhibited normal body weight gain throughout the dosing period of 28 days. No mortality was observed in any of the treatment groups during the course of whole study. Hematological as well as biochemical parameters were unaltered at all three dose levels in Sulbactomax treated rat and mice. From the present study, it can be concluded that Sulbactomax (the fixed dose combination of Ceftriaxone -Sulbactam) is safe even at the dose level which is several folds of the intended human dose.
  A. Soni , M. Chaudhary , A. Tamta , R. Sehgal , S.M. Shrivastava and V.K. Dwivedi
  This study investigated to comapre the efficacy of ofloxacin, ornidazole and mebatic (Fixed dose combination ornidazole plus ofloxacin). Various parameters related to blood, liver and kidney were studied in the monotherapy as well as in the combination therapy. To further explore the mechanisms of better efficacy showed by combination, antioxidant defense status was also explored. The mice were fed standard pelleted diet and water ad libitum. The test room was air conditioned with temperature 22±2°C, humidity 60.5% and with artificial fluorescent light 10-12 h of light and dark, respectively. Twenty four mice were divided into four groups containing six mice in each group. Ofloxacin treated group recieved 3.3 mg kg-1 b.wt. day-1, ornidazole treated group received 8.3 mg kg-1 b.wt. day-1 and mebatic treated group received 11.6 mg kg-1 b.wt. day-1 whereas control group received normal saline. The findings of present study suggested that the combination formulation showed no signs of toxicity when tested for liver and kidney related parameters. The combination formulation also attenuated the oxidative stress and also preserved the antioxidant enzyme levels (catalase and superoxide dismutase) in treated group. From the results of our study it can be concluded that the combination was safe as compared to treatment of the individual agents. It was also infer that the normalized antioxidant defense status might be responsible for decrease in hepatotoxicity and nephrotoxicity in the combination group as compared with monotherapies using either agent.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility